Your browser doesn't support javascript.
loading
Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci.
Kar, Siddhartha P; Adler, Emily; Tyrer, Jonathan; Hazelett, Dennis; Anton-Culver, Hoda; Bandera, Elisa V; Beckmann, Matthias W; Berchuck, Andrew; Bogdanova, Natalia; Brinton, Louise; Butzow, Ralf; Campbell, Ian; Carty, Karen; Chang-Claude, Jenny; Cook, Linda S; Cramer, Daniel W; Cunningham, Julie M; Dansonka-Mieszkowska, Agnieszka; Doherty, Jennifer Anne; Dörk, Thilo; Dürst, Matthias; Eccles, Diana; Fasching, Peter A; Flanagan, James; Gentry-Maharaj, Aleksandra; Glasspool, Rosalind; Goode, Ellen L; Goodman, Marc T; Gronwald, Jacek; Heitz, Florian; Hildebrandt, Michelle A T; Høgdall, Estrid; Høgdall, Claus K; Huntsman, David G; Jensen, Allan; Karlan, Beth Y; Kelemen, Linda E; Kiemeney, Lambertus A; Kjaer, Susanne K; Kupryjanczyk, Jolanta; Lambrechts, Diether; Levine, Douglas A; Li, Qiyuan; Lissowska, Jolanta; Lu, Karen H; Lubinski, Jan; Massuger, Leon F A G; McGuire, Valerie; McNeish, Iain; Menon, Usha.
Affiliation
  • Kar SP; Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK.
  • Adler E; Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.
  • Tyrer J; Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK.
  • Hazelett D; Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK.
  • Anton-Culver H; Bioinformatics and Computational Biology Research Center, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
  • Bandera EV; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
  • Beckmann MW; Department of Epidemiology, Director of Genetic Epidemiology Research Institute, UCI Center for Cancer Genetics Research & Prevention, School of Medicine, University of California Irvine, Irvine, CA 92697, USA.
  • Berchuck A; Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA.
  • Bogdanova N; University Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Universitaetsstrasse 21-23, Erlangen 91054, Germany.
  • Brinton L; Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, NC 27710, USA.
  • Butzow R; Radiation Oncology Research Unit, Hannover Medical School, Hannover 30625, Germany.
  • Campbell I; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA.
  • Carty K; Department of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki 00100, Finland.
  • Chang-Claude J; Cancer Genetics Laboratory, Research Division, Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, VIC 3002, Australia.
  • Cook LS; Department of Pathology, University of Melbourne, Parkville, VIC 3010, Australia.
  • Cramer DW; The Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, UK.
  • Cunningham JM; German Cancer Research Center, Division of Cancer Epidemiology, Heidelberg 69120, Germany.
  • Dansonka-Mieszkowska A; University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg 20246, Germany.
  • Doherty JA; Division of Epidemiology and Biostatistics, Department of Internal Medicine, University of New Mexico, Albuquerque, NM 87131, USA.
  • Dörk T; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, MA 02215, USA.
  • Dürst M; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
  • Eccles D; Department of Pathology, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw 02-781, Poland.
  • Fasching PA; Department of Epidemiology, The Geisel School of Medicine-at Dartmouth, Hanover, NH 03756, USA.
  • Flanagan J; Gynaecology Research Unit, Hannover Medical School, Hannover 30625, Germany.
  • Gentry-Maharaj A; Department of Gynecology, Jena-University Hospital-Friedrich Schiller University, Jena 07737, Germany.
  • Glasspool R; Faculty of Medicine, University of Southampton, Southampton SO16 5YA, UK.
  • Goode EL; University Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Universitaetsstrasse 21-23, Erlangen 91054, Germany.
  • Goodman MT; Division of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA.
  • Gronwald J; Department of Surgery & Cancer, Imperial College London, London SW7 2AZ, UK.
  • Heitz F; Department of Women's Cancer, Institute for Women's Health, University College London, London W1T 7DN, UK.
  • Hildebrandt MA; The Beatson West of Scotland Cancer Centre, Glasgow G12 0YN, UK.
  • Høgdall E; Department of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, MI 55905, USA.
  • Høgdall CK; Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
  • Huntsman DG; Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
  • Jensen A; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin 70-001, Poland.
  • Karlan BY; Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/ Evang. Huyssens-Stiftung/ Knappschaft GmbH, Essen 45136, Germany.
  • Kelemen LE; Department of Gynecology and Gynecologic Oncology, Dr Horst Schmidt Kliniken Wiesbaden, Wiesbaden 65199, Germany.
  • Kiemeney LA; Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  • Kjaer SK; Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen 2100, Denmark.
  • Kupryjanczyk J; Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen 1165, Denmark.
  • Lambrechts D; The Juliane Marie Centre, Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen 2100, Denmark.
  • Levine DA; British Columbia's Ovarian Cancer Research (OVCARE) Program, Vancouver General Hospital, BC Cancer Agency and University of British Columbia, Vancouver, BC V5Z 1L3, Canada.
  • Li Q; Departments of Pathology and Laboratory Medicine and Obstetrics and Gynaecology, University of British Columbia, Vancouver, BC V5Z 1L3, Canada.
  • Lissowska J; Department of Molecular Oncology, BC Cancer Agency Research Centre, Vancouver, BC V5Z 1L3, Canada.
  • Lu KH; Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen 2100, Denmark.
  • Lubinski J; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
  • Massuger LF; Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC 29435, USA.
  • McGuire V; Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen 6500 HB, The Netherlands.
  • McNeish I; Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen 2100, Denmark.
  • Menon U; Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen 2100, Denmark.
Br J Cancer ; 116(4): 524-535, 2017 Feb 14.
Article in En | MEDLINE | ID: mdl-28103614
ABSTRACT

BACKGROUND:

Genome-wide association studies (GWAS) have identified 18 loci associated with serous ovarian cancer (SOC) susceptibility but the biological mechanisms driving these findings remain poorly characterised. Germline cancer risk loci may be enriched for target genes of transcription factors (TFs) critical to somatic tumorigenesis.

METHODS:

All 615 TF-target sets from the Molecular Signatures Database were evaluated using gene set enrichment analysis (GSEA) and three GWAS for SOC risk discovery (2196 cases/4396 controls), replication (7035 cases/21 693 controls; independent from discovery), and combined (9627 cases/30 845 controls; including additional individuals).

RESULTS:

The PAX8-target gene set was ranked 1/615 in the discovery (PGSEA<0.001; FDR=0.21), 7/615 in the replication (PGSEA=0.004; FDR=0.37), and 1/615 in the combined (PGSEA<0.001; FDR=0.21) studies. Adding other genes reported to interact with PAX8 in the literature to the PAX8-target set and applying an alternative to GSEA, interval enrichment, further confirmed this association (P=0.006). Fifteen of the 157 genes from this expanded PAX8 pathway were near eight loci associated with SOC risk at P<10-5 (including six with P<5 × 10-8). The pathway was also associated with differential gene expression after shRNA-mediated silencing of PAX8 in HeyA8 (PGSEA=0.025) and IGROV1 (PGSEA=0.004) SOC cells and several PAX8 targets near SOC risk loci demonstrated in vitro transcriptomic perturbation.

CONCLUSIONS:

Putative PAX8 target genes are enriched for common SOC risk variants. This finding from our agnostic evaluation is of particular interest given that PAX8 is well-established as a specific marker for the cell of origin of SOC.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Cell Transformation, Neoplastic / Gene Amplification / Cystadenocarcinoma, Serous / Neoplasms, Glandular and Epithelial / Genetic Predisposition to Disease / Genetic Loci Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Female / Humans Language: En Journal: Br J Cancer Year: 2017 Type: Article Affiliation country: United kingdom

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Cell Transformation, Neoplastic / Gene Amplification / Cystadenocarcinoma, Serous / Neoplasms, Glandular and Epithelial / Genetic Predisposition to Disease / Genetic Loci Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Female / Humans Language: En Journal: Br J Cancer Year: 2017 Type: Article Affiliation country: United kingdom